The FDA has confirmed that it will convene an advisory committee meeting on 10th June to discuss Eli Lilly’s Alzheimer’s disease candidate donanemab, after announcing a delay to its review earlier ...
When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky. The proliferation of ...